RNA activation

Liver Cancer Pipeline Market Research Report 2022: Comprehensive Insights About 75+ Companies and 75+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 2, 2022
Health, Oncology, Acquisition, Antibody, III, Toxicity, Liver cancer, Route, Pembrolizumab, PD-1, Discovery, IL-27, Myelocyte, NDA, Medicine, HCC, CD27, Cancer, Large-cell lung carcinoma, News, Clinical trial, ADCC, RCC, PD-L1, NSCLC, FDA, Technology, TGF, C/EBP, Patient, RNA activation, Administration, PR, Therapy, Kidney, BMP9, Route of administration, Hepatocellular carcinoma, II, RNA, IND, Dietary supplement, Medical imaging, Pharmaceutical industry, Vaccine, Liver

This Liver Cancer - Pipeline Insight, 2022 report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Liver Cancer pipeline landscape.

Key Points: 
  • This Liver Cancer - Pipeline Insight, 2022 report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Liver Cancer pipeline landscape.
  • A detailed picture of the Liver Cancer pipeline landscape is provided which includes the disease overview and Liver Cancer treatment guidelines.
  • The assessment part of the report embraces, in depth Liver Cancer commercial assessment and clinical assessment of the pipeline products under development.
  • Liver Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

MiNA Therapeutics Presents Proof of Mechanism Data on MTL-STING as a Novel Cancer Immunotherapy

Retrieved on: 
Monday, April 11, 2022
Oncology, Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Cell, Therapy, Sorafenib, RNA activation, AACR, American Association, Cancer, RNA, STING, Immune system, Lists of diseases, Association, Safety, Technology, Mina, Liver cancer, MTL, Gene, HCC, Escape Room, Patient, Vaccine, Pharmaceutical industry

MiNA Therapeutics Limited (MiNA or the Company), the pioneer in small activating RNA (RNAa) therapeutics, presents preclinical proof of mechanism data on MTLSTING as a novel cancer immunotherapy.

Key Points: 
  • MiNA Therapeutics Limited (MiNA or the Company), the pioneer in small activating RNA (RNAa) therapeutics, presents preclinical proof of mechanism data on MTLSTING as a novel cancer immunotherapy.
  • The data validates the drug candidates ability to upregulate the STING protein and related downstream pathways of innate immunity through gene activation.
  • We are very pleased to present this encouraging data and to advance MTL-STING further in development.
  • Upregulating STING presents a novel therapeutic approach to address immune evasion and improve the effectiveness of existing immunotherapies in cancer patients.

First Patient Dosed in Randomised Phase 2 Clinical Trial of MTL-CEBPA in Patients with Advanced Liver Cancer

Retrieved on: 
Tuesday, January 25, 2022
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Viral hepatitis, Therapy, Patient, TKI, RNA, US Foods, Population, ORR, Liver cancer, University College London, HCC, FDA, RNA activation, Sorafenib, Food, MTL, Mina, Progression-free survival, Safety, CRR, Pharmaceutical industry, Medical imaging

OUTREACH-2 is a multi-centre, open-label, randomised study of MTL-CEBPA in combination with sorafenib, compared to sorafenib alone, in TKI-nave advanced pre-treated HCC patients with viral hepatitis etiology.

Key Points: 
  • OUTREACH-2 is a multi-centre, open-label, randomised study of MTL-CEBPA in combination with sorafenib, compared to sorafenib alone, in TKI-nave advanced pre-treated HCC patients with viral hepatitis etiology.
  • This combination treatment demonstrated intriguing signals of activity in a Phase 1b trial, including durable and complete tumour responses.
  • We are very excited to dose our first patient in the OUTREACH-2 study, which is the first Phase 2 clinical trial of a RNAa therapeutic.
  • The study builds on the successful proof-of-concept data from MiNAs first-in-human, Phase 1b clinical trial ( OUTREACH ) evaluating the safety and tolerability of the therapeutic combination in patients with advanced HCC.

MiNA Therapeutics Appoints Two Independent Directors With Extensive Industry Experience to Support Next Phase of Growth

Retrieved on: 
Tuesday, December 21, 2021
Biotechnology, General Health, Pharmaceutical, Health, Technology, Biostatistics, RNA activation, Therapy, Oxford Sciences Innovation, Leadership, Hospital, Mina, Biomedical Research, Lists of diseases, Head, Inflammation, Equity capital markets, Biotechnology, Cell, Chelsea, Chelsea and Westminster Hospital NHS Foundation Trust, Science, Kingdom, Westminster Hospital, Transplant, Autoimmunity, UK Council for Child Internet Safety, Academy, Health, Independent director, Laboratory, RNA, Cancer, Independent, Patient, Growth, Academy of Medical Sciences (United Kingdom), Member, Imperial College London, Pharmaceutical industry, Management, Medicine

In addition, Susan is a member of the Innovation Advisory Group for the Chelsea and Westminster Hospital NHS Foundation Trust.

Key Points: 
  • In addition, Susan is a member of the Innovation Advisory Group for the Chelsea and Westminster Hospital NHS Foundation Trust.
  • Susan Clement-Davies, Independent Director of MiNA Therapeutics, commented:
    I am extremely excited to be joining MiNA.
  • Professor Sir Robert Lechler, Independent Director of MiNA Therapeutics, commented:
    This is a fantastic opportunity to be involved with a pioneering company in such an interesting space.
  • MiNA Therapeutics is the leader in small activating RNA therapeutics.

MiNA Therapeutics Announces Equity Investment From Lilly

Retrieved on: 
Tuesday, July 6, 2021
Research, Finance, Genetics, Professional services, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, RNA, Gene expression, Life sciences, Branches of biology, Biology, Eli Lilly and Company, saRNA, RNA activation, saRNA

MiNA Therapeutics Limited (MiNA or the Company), the pioneer in small activating RNA therapeutics, announces that Eli Lilly and Company has entered into a definitive agreement under which it will make a direct equity investment in MiNA.

Key Points: 
  • MiNA Therapeutics Limited (MiNA or the Company), the pioneer in small activating RNA therapeutics, announces that Eli Lilly and Company has entered into a definitive agreement under which it will make a direct equity investment in MiNA.
  • Proceeds from the equity investment will be used to advance and expand MiNAs internal pipeline of saRNA therapeutics, which is initially focused on immuno-oncology and genetic diseases.
  • This investment from Lilly, together with our recently announced multi-target research collaboration, represents an important endorsement of our saRNA platform.
  • MiNA Therapeutics is the leader in small activating RNA therapeutics.

MiNA Therapeutics Presents Translational Data at AACR Supporting MTL-CEBPA as Immunological Cancer Combination Treatment

Retrieved on: 
Friday, April 9, 2021
Science, Biotechnology, Research, Oncology, Health, Medical devices, Clinical trials, Other Health, Branches of biology, Gene expression, RNA, RNA activation, Biology, American Association for Cancer Research, Cancer research, Checkpoint inhibitor, CEBPA

MiNA Therapeutics, the pioneer in RNA activation (RNAa) therapeutics, today announced translational data supporting the favourable immunological effects of MTL-CEBPA and its benefits in combination with other cancer therapies including anti-PD1 checkpoint inhibition.

Key Points: 
  • MiNA Therapeutics, the pioneer in RNA activation (RNAa) therapeutics, today announced translational data supporting the favourable immunological effects of MTL-CEBPA and its benefits in combination with other cancer therapies including anti-PD1 checkpoint inhibition.
  • The data will be presented during a poster session at the 2021 American Association for Cancer Research (AACR) Annual Meeting, held virtually from April 10 - April 15, 2021.
  • "These new translational findings confirm the important role of MTL-CEBPA in cancer immunology," said Robert Habib, CEO of MiNA Therapeutics.
  • The results validate and expand on previously presented pre-clinical research findings on MTL-CEBPA as an immunological combination treatment in liver cancer and colon cancer .

Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases

Retrieved on: 
Thursday, January 21, 2021
Mental health, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, RNA, Gene expression, RNA activation, saRNA, saRNA, Neurological disorder

Servier, a global and independent pharmaceutical Group, and MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today a research partnership to identify and develop small activating RNA (saRNA) therapies for the treatment of neurological disorders.

Key Points: 
  • Servier, a global and independent pharmaceutical Group, and MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today a research partnership to identify and develop small activating RNA (saRNA) therapies for the treatment of neurological disorders.
  • View the full release here: https://www.businesswire.com/news/home/20210121005329/en/
    As part of the collaboration, MiNA Therapeutics will use its saRNA platform to identify new potential treatments to restore normal cell function in neurological disorders.
  • Under the terms of the agreement, MiNA Therapeutics will receive an upfront payment and an exclusivity fee on certain neurological targets of interest.
  • We are delighted to welcome the MiNA team and to combine their unique approach to restoring cellular function with Servier's focus on treating neurological diseases.

MiNA Therapeutics Appoints Peter Bains as Chief Business Officer

Retrieved on: 
Tuesday, September 29, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, RNA, Gene expression, RNA activation, saRNA

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the appointment of Peter Bains as Chief Business Officer (CBO), effective September 22, 2020.

Key Points: 
  • MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the appointment of Peter Bains as Chief Business Officer (CBO), effective September 22, 2020.
  • Following the recent completion of our Series A financing, MiNA is well-positioned to both advance our clinical development efforts and expand our R&D pipeline to demonstrate the potential of saRNA therapeutics beyond liver cancer, said Robert Habib, CEO of MiNA Therapeutics.
  • Over a 23-year career at GSK, Mr Bains held multiple senior leadership roles in business development, commercial and general management.
  • Harnessing an innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients cells.

MiNA Therapeutics Secures £23 Million Series A Financing to Advance First-in-Class Activating RNA-Based Therapeutics

Retrieved on: 
Thursday, September 10, 2020
Health, Genetics, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, RNA, Gene expression, RNA activation, MiNA Therapeutics, aMoon

MiNA Therapeutics , the pioneer in RNA activation therapeutics, announced today the completion of a 23 million ($30 million) Series A equity financing led by aMoon , Israels largest healthtech and life sciences venture fund, with participation from existing investors.

Key Points: 
  • MiNA Therapeutics , the pioneer in RNA activation therapeutics, announced today the completion of a 23 million ($30 million) Series A equity financing led by aMoon , Israels largest healthtech and life sciences venture fund, with participation from existing investors.
  • As part of the Series A financing, Dr. Gur Roshwalb, M.D., M.B.A., Managing Director at aMoon, has joined the Board of Directors at MiNA Therapeutics.
  • MTS Securities, LLC acted as the exclusive placement agent in connection with the financing.
  • Harnessing an innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients cells.

MiNA Therapeutics Announces Publication of Phase I Liver Cancer Data in Clinical Cancer Research and Provides Update on Clinical Development and Drug Discovery Programs

Retrieved on: 
Wednesday, May 27, 2020
Research, Clinical trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Hepatology, Branches of biology, RNA, Medical specialties, Gene expression, Medicine, RNA activation, Hepatocellular carcinoma, CEBPA, Liver cancer, saRNA, MTL-CEBPA, MiNA Therapeutics

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the publication of data from its Phase I liver cancer trial, OUTREACH, in Clinical Cancer Research.

Key Points: 
  • MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the publication of data from its Phase I liver cancer trial, OUTREACH, in Clinical Cancer Research.
  • In addition, the Company provided an update on its ongoing clinical trials for lead program MTL-CEBPA and its drug discovery programs.
  • This landmark publication in Clinical Cancer Research details for the first time that RNA medicines can activate gene expression, providing clinical benefit to patients, commented Robert Habib, CEO of MiNA Therapeutics.
  • The publication in Clinical Cancer Research summarizes the results from MiNAs Phase I, open-label, dose escalation and dose expansion trial of MTL-CEBPA, OUTREACH, in adults with advanced Hepatocellular Carcinoma (HCC).